文献速递糖尿病

目标范围内时间与糖尿病视网膜病变:1型糖尿病真实世界临床与经济证据

Time in Range and Incident Diabetic Retinopathy: Clinical and Economic Evidence From Real-World Type 1 Diabetes Care.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该回顾性病例队列研究纳入161例使用CGM的1型糖尿病患者,分析TIR与视网膜病变进展的关系。结果显示TIR每增加10%与视网膜病变进展风险降低相关(HR 0.88;95%CI 0.78-0.98),TIR 70%相比40%估计每1000人预防39例失明,经济模型显示每人成本降低2581美元并增加0.13 QALYs。

要点

  • TIR每增加10%与视网膜病变进展风险降低相关(HR 0.88;95%CI 0.78-0.98)。
  • TIR 70%相比40%估计每1000人预防39例失明。
  • 经济模型显示每人成本降低2581美元并增加0.13 QALYs。

核心结论

  • TIR增加与1型糖尿病患者视网膜病变进展风险降低相关,并可能带来失明预防及经济获益。

研究设计与样本

  • 回顾性病例队列研究,纳入161例使用CGM设备的1型糖尿病患者,分析关联的CGM与电子健康记录数据。

主要发现

  • 161例患者中71例为病例(基线HbA1c 8.2%),90例为对照(基线HbA1c 7.3%)。
  • TIR每增加10%,视网膜病变进展风险HR为0.88(95%CI 0.78-0.98)。
  • TIR 70%相比40%,估计每1000人预防39例失明。
  • 经济模拟显示每人成本降低2581美元,增加0.13 QALYs。

关键数值与推荐

  • TIR定义为传感器葡萄糖在70至180 mg/dL之间的时间。

临床怎么用

  • 真实世界CGM研究中可采用多水平混合效应参数生存模型和Markov模型分析TIR与并发症关系。
  • TIR可作为预测1型糖尿病视网膜病变进展及经济结局的指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous glucose monitoring (CGM) metrics are increasingly used to study the relationship between glycemic control and diabetic complications; however, the correlated glucose measurements and unequal follow-up times in real-world CGM data necessitate more advanced analytical approaches to yield unbiased estimates. OBJECTIVE: This retrospective case-cohort study aimed to estimate longitudinal changes in time in range (TIR) on progression to diabetic retinopathy (DR) among patients with type 1 diabetes (T1D). METHODS: This was a retrospective case-cohort study among patients with T1D, using CGM devices. We analyzed linked CGM and electronic health record data from 161 patients with T1D, with long-term follow-up for incident DR diagnoses. TIR was defined as time spent in sensor glucose between 70 and 180 mg/dL. Multilevel mixed-effects parametric survival models and Markov models were constructed to obtain effects of TIR (eg, hazard ratios [HRs]) and lifetime trajectories of developing retinopathy and blindness, respectively. RESULTS: A retrospective case cohort of 161 patients with T1D (mean duration 13.7 years) included 71 cases (baseline glycated hemoglobin A1c [HbA1c] of 8.2%) and 90 controls (baseline HbA1c of 7.3%). A 10% increase in TIR was associated with a modestly lower risk of retinopathy progression (HR 0.88; 95% CI, 0.78-0.98) and an estimated prevention of 39 cases of blindness per 1000 individuals over time (TIR 70% vs 40%). Economic simulation modeling suggested $2581 lower costs per person and a gain of 0.13 quality-adjusted life years (QALYs). CONCLUSION: These findings can guide real-world CGM studies and support diabetes simulation models to predict future treatment outcomes from CGM metrics.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chen NC, Shah VN, McQueen RB, et al. Time in Range and Incident Diabetic Retinopathy: Clinical and Economic Evidence From Real-World Type 1 Diabetes Care. J Clin Endocrinol Metab. 2026. PMID: 41045515. doi:10.1210/clinem/dgaf544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。